Select Publications
Atallah E et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007;110(10):3547-51. Abstract
Estey E et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107(9):3469-73. Abstract
Faderl S et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008a;112(5):1638-45. Abstract
Faderl S et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008b;113(8):2090-6. Abstract
Faderl S et al. Oral (PO) and intravenous (IV) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). Proc ASH 2008c;Abstract 222.
Faderl S et al. Results of an exploratory study of oral (PO) and intravenous (IV) clofarabine in patients with myelodysplastic syndrome. Proc ASH 2007b;Abstract 1455.
Faderl S et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108(1):45-51. Abstract
Faderl S et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105(3):940-7. Abstract
Kantarjian H et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003a;102(7):2379-86. Abstract
Kantarjian HM et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003b;21(6):1167-73. Abstract
Raffoux E et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003;21(12):2326-34. Abstract
Ravandi F et al. Effective treatment of acute promyelocytic leukemia with all-transretinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27(4):504- 10. Abstract
Shen ZX et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101(15):5328-35. Abstract
Tsimberidou AM et al. All-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy induces high rates of durable molecular remission in newly diagnosed acute promyelocytic leukemia (APL). Proc ASH 2007;Abstract 1834.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Gail J Roboz, MD
- Select publications
Stephanie A Gregory, MD
- Select publications
Sundar Jagannath, MD
- Select publications
Guillermo Garcia-Manero, MD
- Select publications
